Kevin Du, MD, PhD, MSCI
Associate Professor of Therapeutic RadiologyCards
About
Research
Publications
2024
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxel
2021
Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848.
Tchelebi L, Winter K, Abrams RA, Safran H, Regine WF, McNulty S, Wu AJ, Du KL, Seaward SA, Bian SX, Aljumaily R, Shivnani AT, Moore T, Crocenzi T, DiPetrillo TA, Kuykendal A, Crane CH, Goodman KA. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: S40. PMID: 34700550, DOI: 10.1016/j.ijrobp.2021.07.114.Peer-Reviewed Original ResearchInterprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
Padilla L, Burmeister JW, Burnett OL, Covington EL, Den RB, Dominello MM, Du KL, Galavis PE, Junell S, Kahn J, Kishore M, Mooney K, Mukhopadhyay ND, Studenski MT, Yechieli RL, Fields EC. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 1058-1065. PMID: 34380009, DOI: 10.1016/j.ijrobp.2021.07.1706.Peer-Reviewed Original ResearchBreaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway.
Modrek AS, Tanese N, Placantonakis DG, Sulman EP, Rivera R, Du KL, Gerber NK, David G, Chesler M, Philips MR, Cangiarella J. Breaking Tradition to Bridge Bench and Bedside: Accelerating the MD-PhD-Residency Pathway. Academic Medicine 2021, 96: 518-521. PMID: 33464738, DOI: 10.1097/acm.0000000000003920.Peer-Reviewed Original Research
2020
Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
Padilla L, Burmeister J, Burnett O, Covington E, Den R, Dominello M, Du K, Galavis P, Junell S, Kahn J, Kishore M, Mooney K, Studenski M, Yechieli R, Fields E. Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e433. DOI: 10.1016/j.ijrobp.2020.07.2517.Peer-Reviewed Original ResearchA Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Nguy S, Du K. A Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e658-e659. DOI: 10.1016/j.ijrobp.2020.07.1972.Peer-Reviewed Original ResearchEffects of M-CSF Inhibition And Radiotherapy In A Murine Model Of Colorectal Cancer
Nguy S, Diskin B, Adam S, Li E, Liria M, Domogauer J, Taneja S, Teruel J, Wang H, Osterman S, Miller G, Du K. Effects of M-CSF Inhibition And Radiotherapy In A Murine Model Of Colorectal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e543-e544. DOI: 10.1016/j.ijrobp.2020.07.1694.Peer-Reviewed Original ResearchA phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Wu J, Atkinson E, Leichman L, Patel H, Iqbal S, Du K, Bizekis C, Goldberg J, Thomas C, Cohen D, Becker D, Siolas D, Beri N, Oberstein P, Ku G. A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2020, 38: 372-372. DOI: 10.1200/jco.2020.38.4_suppl.372.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaClinical CRRadiation therapyPhase I/II studyCarboplatin/paclitaxelEfficacy of nivolumabGrade 2 esophagitisGrade 3/4 AEsGrade 5 toxicityOverall survival benefitPhase II portionSquamous cell carcinomaConcurrent chemoRTManageable toxicityLast dosePrimary endpointII studyUnacceptable toxicityElevated ASTSurvival benefitCell carcinomaChemoRTGrade 3Nivolumab
2019
Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC).
Cohen D, Medina B, Du K, Coveler A, Manji G, Oberstein P, Perna S, Miller G. Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC). Journal Of Clinical Oncology 2019, 37: tps4163-tps4163. DOI: 10.1200/jco.2019.37.15_suppl.tps4163.Peer-Reviewed Original ResearchStereotactic body radiotherapyImmune suppressionResection rateUnacceptable toxicityEfficacy of SBRTPhase II multi-institutional studySingle-arm phase II studyAdvanced unresectable pancreatic cancerArm phase II studyHigher R0 resection rateAdaptive immune suppressionImmune suppressive phenotypeM-CSFPD-1 blockadePhase II studyR0 resection rateStandard induction chemotherapyUnresectable pancreatic cancerSurgical resection rateAnti-tumor responseT cell populationsEfficacy of RTPlacement of fiducialsPre-clinical modelsMulti-institutional study
2018
Survival Outcomes and Prognostic Factors for Gastric Cancer in the Adjuvant Setting: An Analysis of the National Cancer Database
Nguy S, Wu P, Lee A, Tam M, Schreiber D, Du K. Survival Outcomes and Prognostic Factors for Gastric Cancer in the Adjuvant Setting: An Analysis of the National Cancer Database. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e49. DOI: 10.1016/j.ijrobp.2018.07.462.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsA Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
HIC ID2000031055RoleSub InvestigatorPrimary Completion Date02/28/2026Recruiting ParticipantsMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
HIC ID2000027403RoleSub InvestigatorPrimary Completion Date11/15/2025Recruiting ParticipantsPhase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
HIC ID2000024671RoleSub InvestigatorPrimary Completion Date08/31/2026Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Clinical Specialties
Gastrointestinal Radiotherapy; Breast Cancer Radiotherapy; Therapeutic Radiology
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineProstate Cancer
Learn More on Yale MedicineBreast Cancer
Learn More on Yale MedicineSmall Intestine Adenocarcinoma
Learn More on Yale Medicine
Board Certifications
Radiation Oncology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 2012
Yale Medicine News
News & Links
News
- October 24, 2024
Smilow Shares Breast Cancer Awareness: Empowered through Knowledge, Smilow at Trumbull
- November 27, 2023
Kevin Du, MD, PhD, MSCI, in honor of Stomach Cancer Awareness Month
- November 17, 2023
Smilow Shares: Pancreatic Cancer Awareness Day
- September 29, 2023
New Yale Cancer Center Research Highlighted at Top Radiation Oncology Conference